Showing 51 - 60 of 35,663
Persistent link: https://www.econbiz.de/10012504458
Persistent link: https://www.econbiz.de/10012588272
Persistent link: https://www.econbiz.de/10012593406
Persistent link: https://www.econbiz.de/10012547549
Kremer and Snyder (2015) show that demand curves for a preventive and treatment may have different shapes though they target the same disease, biasing the pharmaceutical manufacturer toward developing the lucrative rather than the socially desirable product. This paper tightens the theoretical...
Persistent link: https://www.econbiz.de/10012930337
Persistent link: https://www.econbiz.de/10013369185
Persistent link: https://www.econbiz.de/10013435461
Due to the enormous economic, health, and social costs of the COVID-19 pandemic, there are high expected social returns to investing in parallel in multiple approaches to accelerating vaccination. We argue there are high expected social returns to investigating the scope for lowering the dosage...
Persistent link: https://www.econbiz.de/10013213673
We argue that in pharmaceutical markets, variation in the arrival time of consumer heterogeneity creates differences between a producer’s ability to extract consumer surplus with preventives and treatments, potentially distorting R&D decisions. If consumers vary only in disease risk, revenue...
Persistent link: https://www.econbiz.de/10014151001
Advance market commitments (AMCs) provide a mechanism to stimulate investment by suppliers of products to low-income countries. In an AMC, donors commit to a fund from which a specified subsidy is paid per unit purchased by low-income countries until the fund is exhausted, strengthening...
Persistent link: https://www.econbiz.de/10014090274